Payment overview · 2025
General Payments
$264.22
11 reported records · 6 companies
Healthcare provider profile · identity verified
Cyril M Simon, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · EUNICE, NM · NPI 1023050929
Verified facts
What the public records show
CMS Open Payments records show Cyril M Simon, D.O. received $264.22 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 57.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $150.85 | 57.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $47.89 | 18.1% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.10 | 6.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.83 | 6.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.27 | 6.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $14.28 | 5.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $247.95 | 10 |
| Education | $16.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $123.33 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $106.13 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $105.81 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $47.89 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.10 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 92 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
85 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
92 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 708 | 180 |
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 125 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 336 | 58 |
| Amlodipine Besylate | Amlodipine Besylate | 314 | 89 |
| Gabapentin | Gabapentin | 287 | 74 |
| Potassium Chloride | Potassium Chloride | 259 | 75 |
| Metformin Hcl | Metformin Hcl | 253 | 76 |
| Lisinopril | Lisinopril | 237 | 67 |
| Losartan Potassium | Losartan Potassium | 214 | 62 |
| Metoprolol Succinate | Metoprolol Succinate | 212 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 209 | 65 |
| Omeprazole | Omeprazole | 204 | 59 |
| Furosemide | Furosemide | 188 | 61 |
| Allopurinol | Allopurinol | 163 | 36 |
| Temazepam | Temazepam | 162 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 161 | 43 |
| Tramadol Hcl | Tramadol Hcl | 150 | 39 |
| Simvastatin | Simvastatin | 148 | 36 |
| Mounjaro | Tirzepatide | 147 | 22 |
| Montelukast Sodium | Montelukast Sodium | 142 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 137 | 42 |
| Eliquis | Apixaban | 134 | 24 |
| Famotidine | Famotidine | 126 | 41 |
| Carvedilol | Carvedilol | 125 | 42 |
| Glimepiride | Glimepiride | 124 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 33 |
| Trazodone Hcl | Trazodone Hcl | 107 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 28 |
| Tizanidine Hcl | Tizanidine Hcl | 95 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 92 | 24 |
| Ozempic | Semaglutide | 92 | 26 |
| Sertraline Hcl | Sertraline Hcl | 89 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 25 |
| Alendronate Sodium | Alendronate Sodium | 86 | 33 |
| Synthroid | Levothyroxine Sodium | 85 | 22 |
| Alprazolam | Alprazolam | 83 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 80 | 17 |
| Meloxicam | Meloxicam | 77 | 27 |
| Azithromycin | Azithromycin | 76 | 65 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 75 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 24 |
| Ezetimibe | Ezetimibe | 73 | 20 |
| Bupropion Xl | Bupropion Hcl | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 47 |
| Jardiance | Empagliflozin | 63 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 17 |
| Nifedipine Er | Nifedipine | 57 | 18 |
| Baclofen | Baclofen | 54 | 15 |
| Buspirone Hcl | Buspirone Hcl | 54 | 16 |
| Spironolactone | Spironolactone | 52 | 20 |
| Trulicity | Dulaglutide | 49 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Finasteride | Finasteride | 44 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 44 | 11 |
| Donepezil Hcl | Donepezil Hcl | 42 | 16 |
| Enalapril Maleate | Enalapril Maleate | 42 | 11 |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 11 |
| Prednisone | Prednisone | 38 | 20 |
| Tradjenta | Linagliptin | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 25 |
| Methylprednisolone | Methylprednisolone | 36 | 29 |
| Celecoxib | Celecoxib | 34 | 12 |
| Chlorthalidone | Chlorthalidone | 34 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 11 |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 31 | 16 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 11 |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Naproxen | Naproxen | 29 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 11 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 26 | suppressed |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Gemfibrozil | Gemfibrozil | 23 | suppressed |
| Glipizide | Glipizide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Ciclopirox | Ciclopirox | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 18 | 12 |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nystatin | Nystatin | 16 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Clonazepam | Clonazepam | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $264.22 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BEXSERO, BREZTRI, FARXIGA, Ozempic, QULIPTA, REXULTI, SHINGRIX, TONMYA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error